Filing Flows

Filing Flows › Heron Therapeutics (HRTX) › Takeover & LBO

Is Heron Therapeutics (HRTX) a takeover target?

A leveraged buyout does not work for Heron Therapeutics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-11-09): CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care.

Why a leveraged buyout does not fit

The buyout model needs Heron Therapeutics' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.

What a takeover could cost

Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.

Rumors and deal signals

Heron Therapeutics' latest quarter

Heron Therapeutics, Q3 2026: revenue $35.2M (-8% year over year), operating margin -4.7%, net loss $5.0M, operating cash flow −$794K. The chart follows the revenue to costs, profit and cash.

Questions

Is Heron Therapeutics being acquired?

The latest signal on file is from 2026-11-09: CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care. A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.

Could private equity buy Heron Therapeutics?

A leveraged buyout does not work for Heron Therapeutics on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.

Open the interactive view →

Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.